

Cover Page

CRD number, if applicable of intermediary:
003503

Select the jurisdictions in which the issuer intends to offer the securities:

AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY, BS, GU, PR, VI, VJ

Be very careful and precise in answering all questions. Give full and complete answers so that they are not misleading under the circumstances involved. Do not discuss any future performance or other anticipated event unless you have a reasonable basis to believe that it will actually occur within the foreseeable future. If any answer requiring significant information is materially inaccurate, incomplete or misleading, the Company, its management and principal shareholders may be liable to investors based on that information.

4. Provide the following information about each director (and any persons occupying a similar status or performing a similar function) of the issuer:

For three years of business experience, refer to Appendix I3: Director & Officer Work History.

5. Provide the following information about each officer (and any persons occupying a similar status or performing a similar function) of the issuer:

For three years of business experience, refer to Appendix D: Director & Officer Work History.

INSTRUCTION TO QUESTION 3: For purposes of this Question 3, the term officer means a president, vice president, secretary, treasurer or principal financial officer, controller or principal accounting officer, and any person performing similar functions.

f. Provide the name and ownership level of each person, as of the most recent practicable date, who is the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power.

INSTRUCTION TO QUESTION 6: The nurse information must be provided as if you were that is no more than 170 days prior to the date of filing of this financial statement.

In calculating total voting power, securities are assumed to be held by the person directly or indirectly who is shown the voting power which includes the power to vote or to direct the voting of such securities. If the person has the right to acquire voting power of such securities with 60 days, by holding through the exercise of any option, security or right to convertation of a security, or under a contingency, if the security can be held by a member of the family, through representation or partnership, or otherwise in a manner that would allow a person to direct or control the voting of the securities (or there is such indication or intent . . . as the person is co-owner) they should be included as being "indirectly owned." No such inclusion is explained in their concentration in a footnote to the "Number and Class of Securities Now Held." In calculating outstanding voting equity, securities assume all outstanding options are exercised and all outstanding convertible securities converted.

7. Describe in detail the business of the issuer and the anticipated business plan of the issuer.

For a description of our business and our business plan, please refer to the attached Appendix A, Business Description & Plan.

INSTRUCTION TO QUESTION 7: Respondent will provide your company's Respondent profile as an appendix (Appendix A) to the survey in PDF format. The submission will include all Q&A items and "lead notes" (if in an uncollected format). A index will be transmitted.

This means that any information provided in your Wyndor profile will be provided to the SEC in response to this question. As a result, your company will be potentially liable for misstatements and omissions in your profile under the Securities Act of 1933, which requires you to provide material information related to your business and anticipated business plan. Please review your Wyndor profile carefully to ensure it provides all material information, is not false or misleading, and does not omit any information that would cause the information included to be false or misleading.

RISK FACTORS

The U.S. Securities and Exchange Commission does not pass upon the merits of

1. Do these securities represent securities as defined in Regulation D? (Select "Yes" if you are providing information regarding the offering of securities, or "No" if you are not.)

Any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

8. Discuss the material factors that make an investment in the issuer speculative or risky.

Research and development in biotechnology is not a sure bet. Hypotheses can be null and proof of concepts can fail. There is no sure bet that LEAH Labs can generate a therapy that will rival the current standard of care.

We have performed "freedom to operate" scans, but there can be no guarantee that our portfolio of technology is free from being subjected to licensing fees, taking money out of our bottom dollar and the ability to grow revenue to the levels we aim for.

This Wefunder campaign raises us money to take our R&D to the next level and trial our MVP in patient dogs. This campaign does not get us to market and does not guarantee we will ever get to market.

Immunotherapy like CAR-T cell therapy can cause severe toxicities and even death in humans. We hypothesize the same toxicities are possible in our canine friends. Should managing these toxicities prove cost-prohibitive in dogs, our therapeutic strategy may fail.

CAR-T cell therapy is the hottest area of cancer research today. Headlines, both positive and negative, will impact our business and veterinarians will agnress to try our product during the experimental phase.

The SEC recently approved amendments to Regulation Crowdfunding in which the fundraising limit for crowdfunding issuers will be increased from \$1.07 million during a 12-month period to \$5 million during a 12-month period. These amendments will take effect 60 days after the publication in the Federal Register. The Company reserves the right to increase the Maximum Fundraising Target once such amendments have effect. If the Company increases the Maximum Fundraising Target, investments made prior to such limit increase may be diluted accordingly.

The Company may never receive a future equity financing or elect to convert the Securities upon such future financing. In addition, the Company may never undergo a liquidity event such as a sale of the Company or an IPO. If neither the conversion of the Securities nor a liquidity event occurs, the Purchasers could be left holding the Securities in perpetuity. The Securities have numerous transfer restrictions and will likely be highly illiquid, with no secondary market on which to sell them. The Securities are not equity interests, have no ownership rights, have no rights to the Company's assets or profits and have no voting rights or ability to direct the Company or its actions.

Our future success depends on the efforts of a small management team. The loss of services of the members of the management team may have an adverse effect on the company. There can be no assurance that we will be successful in attracting and retaining other personnel we require to successfully grow our business.

INSTRUCTIONS TO QUESTION 8: Read general instructions and include only those factors that are unique to the issuer. Do not include information that is common to the offering and should be included in the offering document. Do not include information that is common to the offering and should be included in the offering document. Do not include information that is common to the offering and should be included in the offering document.

Ownership and Capital Structure

DESCRIPTION OF ISSUERS SECURITIES

12. What other securities or classes of securities of the issuer are outstanding? Describe the material terms of any other outstanding securities or classes of securities of the issuer.

Class of Security	Securities (or Amount) Authorized	Securities (or Amount) Outstanding	Voting Rights
Common stock	10,000,000	4,898,570	Yes

Securities Reserved for Issuance upon Exercise or Conversion

Warrants:

Options:

24. Describe the material terms of any indebtedness of the issuer.

None

INSTRUCTIONS TO QUESTION 24: Name the lender, interest rate, interest rate, date, and any other material terms.

25. What other exempt offerings has the issuer conducted within the last three years?

Offering Date	Exemption	Security Type	Amount Sold	Use of Proceeds
1/2019	Section 4(a)(2)	SAFE	\$100,000	General operations
1/2019	Section 4(a)(2)	SAFE	\$30,000	General operations
3/2019	Section 4(a)(2)	SAFE	\$35,000	General operations
4/2019	Section 4(a)(2)	SAFE	\$10,000	General operations
4/2019	Section 4(a)(2)	SAFE	\$10,000	General operations
11/2019	Regulation D, Rule 506(c)	SAFE	\$3,000	General operations
11/2019	Regulation D, Rule 506(c)	SAFE	\$10,000	General operations
2/2020	Regulation D, Rule 506(c)	SAFE	\$100,000	General operations
2/2020	Regulation D, Rule 506(c)	SAFE	\$168,338	General operations
3/2020	Regulation D, Rule 506(c)	SAFE	\$10,000	General operations
7/2021	Section 4(a)(2)	SAFE	\$10,000	General operations
8/2021	Section 4(a)(2)	SAFE	\$25,000	General operations
8/2021	Section 4(a)(2)	SAFE	\$25,000	General operations
8/2021	Section 4(a)(2)	SAFE	\$10,000	General operations
9/2021	Section 4(a)(2)	SAFE	\$20,000	General operations
9/2021	Section 4(a)(2)	SAFE	\$10,000	General operations
9/2021	Section 4(a)(2)	SAFE	\$75,000	General operations
10/2021	Section 4(a)(2)	SAFE	\$30,000	General operations
10/2021	Section 4(a)(2)	SAFE	\$100,000	General operations
10/2021	Section 4(a)(2)	SAFE	\$40,000	General operations
11/2021	Section 4(a)(2)	SAFE	\$20,000	General operations
1/2022	Section 4(a)(2)	SAFE	\$100,000	General operations
1/2022	Section 4(a)(2)	SAFE	\$100,000	General operations
2/2022	Section 4(a)(2)	SAFE	\$30,000	General operations
4/2022	Section 4(a)(2)	SAFE	\$30,000	General operations
5/2022	Section 4(a)(2)	SAFE	\$10,000	General operations
8/2022	Section 4(a)(2)	SAFE	\$100,000	General operations
8/2022	Section 4(a)(2)	SAFE	\$25,000	General operations
7/2022	Section 4(a)(2)	SAFE	\$300,000	General operations
7/2022	Section 4(a)(2)	SAFE	\$15,000	General operations
7/2022	Section 4(a)(2)	SAFE	\$15,000	General operations
7/2022	Section 4(a)(2)	SAFE	\$75,000	General operations

7/2022	Section 4(a)(2)	SAFE	\$10,000	General operations
7/2022	Section 4(a)(2)	SAFE	\$50,000	General operations
8/2022	Section 4(a)(2)	SAFE	\$50,000	General operations
8/2022	Section 4(a)(2)	SAFE	\$25,000	General operations
9/2022	Section 4(a)(2)	SAFE	\$50,000	General operations
10/2022	Section 4(a)(2)	SAFE	\$200,000	General operations

26. Was or is the issuer or any entities controlled by or under common control with the issuer a party to any transactions since the beginning of the issuer's last fiscal year, or any currently proposed transaction, where the amount involved exceeds five percent of the aggregate amount of capital raised by the issuer in reliance on Section 4(a)(3) of the Securities Act during the preceding 12-month period, including the amount the issuer seeks to raise in the current offering, in which any of the following persons had or is to have a direct or indirect material interest:

- any director or officer of the issuer;
 - any person who is, as of the most recent practicable date, the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power;
 - if the issuer was incorporated or organized within the past three years, any promoter of the issuer;
 - or any immediate family member of any of the foregoing persons.
- ☒ Yes
☐ No

For each transaction specify the person, relationship to issuer, nature of interest in transaction, and amount of interest.

Name	Stephen Eklor
Amount Invested	\$100,000.00
Transaction type	Safe
Issue date	06/15/22
Valuation cap	\$12,000,000.00
Relationship	Founder and Board Director

INSTRUCTIONS TO QUESTION 26: The term transaction includes, but is not limited to, any financial transaction, direct or indirect, including any indebtedness or issuance of debt (debt), or any series of similar transactions, arrangements or relationships.

Beneficial ownership for purposes of paragraph (2) shall be determined as of a date that is no more than 120 days prior to the date of filing of this offering statement and using the same calculation described in Question 6 of the Questions and Answers herein.

The term "member of the family," includes any child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spouse equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the person, and includes adoptive relationships. The term "beneficial ownership" means a substantial economic relationship, regardless of the form of ownership.

Compute the amount of a shareholder's interest by using the amount of the interest in the shares of the issuer as a percentage of the transaction. Where it is not practicable to state the approximate amount of the interest, describe the approximate amount involved in the transaction.

FINANCIAL CONDITION OF THE ISSUER

27. Does the issuer have an operating history?

- ☒ Yes
☐ No

28. Describe the financial condition of the issuer, including the extent of assets, liquidity, capital resources and historical results of operations.

Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

Human's best science for human's best friend 🐾👨🏻👩🏻👪

Dogs are part of the family and we don't feel that the current care they get is up to par; they deserve the same technological advances in healthcare that their humans get. Using our expertise in gene editing, we can bring innovation to the veterinary market that has never before been possible.

LEAH Labs uses next generation technology to reprogram immune cells into cancer fighting machines.

In 5 years, we hope LEAH Labs has the only treatment in canine oncology that can CURE cancer. We hope to have diversified our portfolio and now treat multiple cancer types. We hope the data we have generated and the platform we have built are licensed to a leading human immuno-oncology company. We hope we've expanded and have cell therapy products across a range of disease. While these projections cannot be guaranteed, we're working hard every day for our pet!

Milestones

Lifeline Animal Health Laboratories incorporated was incorporated in the State of Delaware in November 2018.

Since then, we have:

- 🐾 We're developing a cost effective cell therapy to cure cancer in dogs. It's proven in humans.
- 🐾 Your funding goes DIRECTLY to our pilot trials in dogs with cancer
- 🐾 \$50,000+ committed outside of our funders during this round
- 🐾 Awarded \$394,000 in grant funding to date, including a National Science Foundation Phase I SBIR
- 🐾 Growing companion animal market: Over 80M dogs in the USA, \$100B+ yearly spend in the space.
- 🐾 100M dogs die from cancer each year and we're on track to get to market by 2024 to help
- 🐾 We're a team of world leading experts in gene editing, immunotherapy, and veterinary oncology.

The Company is subject to risks and uncertainties common to early stage companies. Given the Company's limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future.

Historical Results of Operations

- Revenue & Gross Margin:** For the period ended December 31, 2022, the Company had revenue of \$0 compared to the year ended December 31, 2021, when the Company had revenue of \$0. Our gross margin was 0% in fiscal year 2022, compared to 0% in 2021.
- Assets:** As of December 31, 2022, the Company had total assets of \$1,620,430.85, including \$128,859.07 in cash. As of December 31, 2021, the Company had \$59,240.37 in total assets, including \$89,883.40 in cash.
- Net Loss:** The Company has had net loss of \$468,270.24 and net losses of \$340,788.60 for the fiscal years ended December 31, 2022 and December 31, 2021, respectively.
- Liabilities:** The Company's liabilities totaled \$2,042,569.22 for the fiscal year ended December 31, 2022 and \$3,784,907.48 for the fiscal year ended December 31, 2021.

Related Party Transaction

Refer to Question 26 of this Form C for disclosure of all related party transactions.

Liquidity & Capital Resources

To-date, the company has been financed with \$2,944,493 in SAFEs.

After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 15 months before we need to raise further capital.

We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don't have any other sources of capital in the immediate future.

We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 1 month. Except as otherwise described in this Form C, we do

not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early stage companies, there is no guarantee that the Company will receive any investments from investors.

Runway & Short/Mid Term Expenses

LifEngine Animal Health Laboratories Incorporated cash in hand is \$1,198,076.70, as of April 2023. Over the last three months, revenues have averaged \$0/month, cost of goods sold has averaged \$0/month, and operational expenses have averaged \$69,028/month, for an average burn rate of \$69,028 per month. Our intent is to be profitable in 40 months.

We have not had any material changes to our record financials since the date our finances cover. We currently, however, have \$1.5M in grant funding pending.

We expect \$0 in revenue in the next 3-6 months as we are an R&D and clinical stage biotech company. We expect -\$450,000 in expenses in the next 6 months as we enroll patients in our pilot efficacy trials in patient dogs and continue R&D.

We are not profitable. We are an R&D stage biotech company and do not intend to be profitable until 2025, when we could potentially have our first commercial sales.

We have ~55% in grant funding left to spend and will be reimbursed. We have \$1.5M in grant funding pending.

We will be writing and submitting 2-3 additional grants in the next calendar year.

We intend to launch a Series A fundraise in the next 6-8 months.

All projections in the above narrative are forward looking and not guaranteed.

INSTRUCTIONS TO QUESTION 24: The disclosure must cover each year for which financial statements are provided. For issuers with no prior operating history, the disclosure should focus on financial, business and operational, liquidity and other challenges, or other risk or operating factors, the disclosure should focus on investor demand, capital and cash. See an representative of what investors should expect in the future. Take into account the position of the offering and any other known or pending sources of capital. Investors have the power to fund the offering will affect liquidity whether creating their funds and they are not allowed to fund the costs of the offering of the business, and the quality of the funds and the quality of the capital. Since the other available sources of capital in the business, most of them are likely to require compensation in the future. Therefore, to the extent of the Question 24 and these instructions refer to the subject and to investors, (CFO).

FINANCIAL INFORMATION


24. Include financial statements covering the two most recently completed fiscal years or the period(s) since inception, if shorter:

Refer to [Appendix C: Financial Statements](#)

I, Wesley A Wiersen, certify that:

(1) the financial statements of LifEngine Animal Health Laboratories Incorporated included in this Form are true and complete in all material respects; and

(2) the financial information of LifEngine Animal Health Laboratories Incorporated included in this Form reflects accurately the information reported on the tax return for LifEngine Animal Health Laboratories Incorporated filed for the most recently completed fiscal year.


Wesley A Wiersen
CEO

OTHER MATERIAL INFORMATION

31. In addition to the information expressly required to be included in this Form, include:

- (1) any other material information presented to investors; and
- (2) such further material information, if any, as may be necessary to make the required statements, in the light of the circumstances under which they are made, not misleading.

The Company is using the services of XX as part of its offering. XX is comprised of XX Investments, LLC, XX Team, LLC, and the Lead Investors who provide services on behalf of XX Team, LLC. The services of XX are available to companies that offer securities through Wefunder Portal LLC and to investors who invest in such companies through Wefunder Portal, but XX is not affiliated with Wefunder Portal or its affiliates.

XX Investments is the Company's transfer agent and also acts as custodian, paying agent, and proxy agent on behalf of all investors that enter into the Custodial and Voting Agreement with XX Investments through the Wefunder Portal website ("investors"). XX Investments holds legal title to the securities the Company issues through Wefunder Portal (which are unregistered) on behalf of investors. Investors, in turn, have the beneficial interests in the Company's securities. XX Investments keeps track of each investor's beneficial ownership interest and makes any distributions to the investors (or other parties, as directed by the investors).

In addition to the above services, at the direction of XX Team, XX Investments votes the securities and take any other actions in connection with such voting on behalf of the investors. XX Investments acts at the direction of XX Team, because XX Team holds a power of attorney from each investor that has entered into the Investor Agreement to make voting decisions on behalf of that investor. XX Investments will not charge investors for its services. XX Investments does charge the Company \$1,000/year for services; however, those fees may be paid by Wefunder Inc. on behalf of the Company.

As noted, XX Team holds a power of attorney from each investor that has entered into the Investor Agreement to make voting decisions on behalf of that investor. Pursuant to the power of attorney, XX Team will make voting decisions and then direct XX Investments to vote and take any other actions in connection with the voting on investors' behalf. XX Team will act with respect to the Company. Through our Lead Investor, who is a representative of XX Team. As compensation for its voting services, each investor authorizes XX Investments to distribute to XX Team 10% of any distributions the investor would otherwise receive from the Company. XX Team will share its compensation with our Lead Investor. XX Team, through our Lead Investor, may also provide consulting services to the Company and may be compensated for these services by the Company, although, fees owed by the Company may be paid by Wefunder Inc. XX Team will share its consulting compensation with our Lead Investor.

The Lead Investor is an experienced investor that we choose to act in the role of Lead Investor, both on behalf of the Company and on behalf of investors. As noted, the Lead Investor will be a representative of XX Team and will share in compensation that XX Team receives from the Company or Wefunder Inc. on the Company's behalf or from investors. The Lead Investor will be chosen by the Company and approved by Wefunder Inc., and the identity of the Lead Investor must be disclosed to investors before investors make a final investment decision to purchase the Company's securities. Investors will receive disclosure regarding all fees that may be received by the Lead Investor, in addition to the fees described above, the Lead Investor may receive compensation if, in the future, Wefunder Advisors LLC forms a special purpose vehicle ("SPV") for the purpose of investing in a non-Regulation Crowdfunding offering of the Company. In such a circumstance, the Lead Investor may act as a portfolio manager for that SPV (and as a supervised person of Wefunder Advisors) and may be compensated through that role. Although the Lead Investor may act in multiple roles and be compensated from multiple parties, the Lead Investor's goal is to maximize the value of the Company and therefore maximize the value of the Company's securities. As a result, the Lead Investor's interests should always be aligned with those of the investors.

Investors that wish to purchase the Company's securities through Wefunder Portal must agree to (1) hire XX Investments to serve as custodian, paying agent, and proxy agent with respect to the Company's securities; (2) give a power of attorney to XX Team to make all voting decisions with respect to the Company's securities; and (3) direct XX Investments to share 10% of the investor's distribution from the Company with XX Team. The Company may waive these requirements for certain investors with whom the Company has a pre-existing relationship.

The XX arrangement described above is intended to benefit the Company by allowing the Company to select one investor of its own choosing to act as the Lead Investor and by simplifying the voting process with respect to the Company's securities by having one entity (XX Team), through one person (the Lead Investor), make all voting decisions and having one entity (XX Investments) carry out XX Team's voting instructions and any take any other actions. The XX arrangement also is intended to benefit investors by providing the services of an experienced Lead Investor (acting on behalf of XX Team) who is expected to make value-maximizing decisions regarding investors' securities. XX Team (acting through the Lead Investor) may further benefit both the Company and investors by providing consulting services to the Company that are intended to maximize both the value of the Company's securities and also the value of its securities.

INSTRUCTIONS TO QUESTION 31: If information is provided to increase in detail, under a different heading and also in the form of a separate document, the user should include a description of the nature of each document.

31.1. Description of the nature of each document.

ONGOING REPORTING

32. The issuer will file a report electronically with the Securities & Exchange Commission annually and post the report on its website, no later than:
120 days after the end of each fiscal year covered by the report.

33. Once posted, the annual report may be found on the issuer's website at:
<http://www.leahlabs.com/invest>

The issuer must continue to comply with the ongoing reporting requirements until:

1. the issuer is required to file reports under Exchange Act Sections 13(a) or 15(d);
2. the issuer has filed at least one annual report and has fewer than 300 holders of record;
3. the issuer has filed at least three annual reports and has total assets that do not exceed \$10 million;
4. the issuer or another party purchases or repurchases all of the securities issued pursuant to Section 4(a)(6), including any payment in full of debt securities or any complete redemption of redeemable securities, or the issuer liquidates or dissolves in accordance with state law.

APPENDICES

[Appendix A: Business Description & Plan](#)

[Appendix C: Financial Statements](#)

[Financials I](#)

[Appendix D: Director & Officer Work History](#)

[Stephen C. Ekker](#)
[Wesley A. Wiersen](#)

[Appendix E: Supporting Documents](#)

[Add new Form C attachments \(tables only\)](#)

Signatures

Intentional misstatements or omissions of facts constitute federal criminal violations. See 18 U.S.C. 1001.

The following documents will be filed with the SEC:

Cover Page XML

Offering Statement (this page)

[Appendix A: Business Description & Plan](#)

[Appendix B: Investor Contracts](#)

[Early Bird SAFE \(Simple Agreement for Future Equity\)](#)

[SAFE \(Simple Agreement for Future Equity\)](#)

[Appendix C: Financial Statements](#)

[Financials I](#)

[Appendix D: Director & Officer Work History](#)

[Stephen C. Ekker](#)
[Wesley A. Wiersen](#)

[Appendix E: Supporting Documents](#)

Pursuant to the requirements of Sections 4(a)(6) and 4(A) of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing an Annual Report and has duly caused this form to be signed on its behalf by the duly authorized undersigned.

LifeEngine Animal Health
Laboratories Incorporated

By

Wesley Wiersen
Chief Executive Officer

Pursuant to the requirements of Sections 4(a)(6) and 4(A) of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the Annual Report and Transfer Agent Agreement has been signed by the following persons in the capacities and on the dates indicated.

Stephen Carl Ekker

Director
4/16/2023

Wesley Wiersen

Chief Executive Officer
4/13/2023